+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Immunoglobulins treatment in multiple sclerosis and experimental autoimmune encephalomyelitis



Immunoglobulins treatment in multiple sclerosis and experimental autoimmune encephalomyelitis



Multiple Sclerosis 6 Suppl 2: S6-8; Discussion S33



Intravenously administered immunoglobulins (IgG) treatment has several modes of action that can regulate the immune response during different steps of the inflammatory process in experimental autoimmune encephalomyelitis (EAE) and Multiple Sclerosis (MS). The immunomodulatory effects IgG are largely dependent on their ability to interact with membrane molecules of lymphocytes and monocytes. Better understanding of these mechanisms of action in relation to the pathogenesis of MS, is important in order to decide the time of initiation and the duration of treatment in MS patients. In order to have the best beneficial effect on disease course, future research should focus on the initial events that activate the disease and on the early treatment modalities of IgG in MS.

(PDF emailed within 1 workday: $29.90)

Accession: 046333413

Download citation: RISBibTeXText

PMID: 11188777


Related references

Riluzole suppresses experimental autoimmune encephalomyelitis: implications for the treatment of multiple sclerosis. Brain Research 989(2): 196-204, 2003

Intravenous immunoglobulin treatment in Multiple Sclerosis and experimental autoimmune encephalomyelitis - the Israeli Experience. Multiple Sclerosis Journal 3(2): 142-144, 1997

The role of interferon-β in the treatment of multiple sclerosis and experimental autoimmune encephalomyelitis - in the perspective of inflammasomes. Immunology 139(1): 11-18, 2013

Intravenous immunoglobulin treatment of multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis. Journal of the Neurological Sciences 233(1-2): 61-65, 2005

Estriol treatment ameliorates disease in males with experimental autoimmune encephalomyelitis: implications for multiple sclerosis. Journal of Neuroimmunology 149(1-2): 84-89, 2004

Dexanabinol (HU-211) effect on experimental autoimmune encephalomyelitis: Implications for the treatment of acute relapses of multiple sclerosis. Journal of Neuroimmunology 102(1): 26-31, 2000

Endogenous opioids regulate expression of experimental autoimmune encephalomyelitis: a new paradigm for the treatment of multiple sclerosis. Experimental Biology and Medicine 234(11): 1383-1392, 2009

Intravenous gammaglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis: delineation of usage and mode of action. Journal of Neurology, Neurosurgery, and Psychiatry 57 Suppl: 57-61, 1994

Intravenous immunoglobulin treatment in multiple sclerosis and experimental autoimmune encephalomyelitis--the Israeli experience. MS Study Group. Multiple Sclerosis 3(2): 142-144, 1997

Improved clinical behavior of established relapsing-remitting experimental autoimmune encephalomyelitis following treatment with endogenous opioids: implications for the treatment of multiple sclerosis. Brain Research Bulletin 112: 42-51, 2015

Spasticity Treatment Ameliorates the Efficacy of Melatonin Therapy in Experimental Autoimmune Encephalomyelitis (EAE) Mouse Model of Multiple Sclerosis. Cellular and Molecular Neurobiology: -, 2018

A case for regulatory B cells in controlling the severity of autoimmune-mediated inflammation in experimental autoimmune encephalomyelitis and multiple sclerosis. Journal of Neuroimmunology 230(1-2): 1-9, 2011

The trimolecular complex as a target for specific immunotherapy in experimental autoimmune encephalomyelitis--applications for multiple sclerosis and other human autoimmune disease. Harefuah 123(3-4): 110-115, 1992

A B Cell-Driven Autoimmune Pathway Leading to Pathological Hallmarks of Progressive Multiple Sclerosis in the Marmoset Experimental Autoimmune Encephalomyelitis Model. Frontiers in Immunology 8: 804-804, 2017

Multiple sclerosis and experimental autoimmune encephalomyelitis. La Revue du Praticien 44(1): 69-74, 1994